NCT04895579View on ClinicalTrials.gov

Lung Cancer With Copanlisib and Durvalumab

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 12, 2021

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Durvalumab

Durvalumab will be delivered at 10mg/kg via IV infusion at days 1 and 15 every 28 days or 1500 mg on D1, q4w.

DRUG

Copanlisib

Copanlisib will be delivered at various doses (30-60mg/kg) via IV infusion at days 1 and 15 every 28 days.

Trial Locations (1)

40536

Markey Cancer Center, Lexington

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Zhonglin Hao

OTHER